Internship

Spring 2025 Co-op: Cell & Molecular Biology

Posted on 9/6/2024

Prime Medicine

Prime Medicine

201-500 employees

Gene editing technology for genetic diseases

Biotechnology
Healthcare

No H1B Sponsorship

Cambridge, MA, USA

Candidates must be local to the Boston/Cambridge area.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • B.S/M.S. candidate in Cell & Molecular Biology or related major
  • Basic knowledge of molecular biology, cell biology and biochemistry.
  • Excellent troubleshooting and communication skills
  • Ability to work independently and within a team
Responsibilities
  • Aseptic mammalian cell culture, including passaging and performing transfections to evaluate Prime Editor activity.
  • Cloning of Prime editor components into suitable expression vectors
  • DNA, RNA, and protein extraction from in vitro and in vivo samples
  • Sample preparation to confirm Prime Editing using various techniques including NGS, ddPCR, qPCR, and ELISAs
  • Data analysis, interpretation, and team presentation
  • Electronic lab notebook documentation

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Unlike many competitors, Prime Medicine collaborates with research institutions and pharmaceutical companies to advance its technology and bring it to market, generating revenue through licensing and partnerships. The leadership team has significant experience in developing innovative medicines, highlighting the company's commitment to enhancing its capabilities and operations.

Company Stage

IPO

Total Funding

$306.4M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

2%

1 year growth

7%

2 year growth

45%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships, like with Bristol Myers Squibb, offer significant financial and developmental benefits.
  • Increased investment interest, such as the $15M from CF Foundation, boosts research capabilities.
  • The $161M PIPE offering provides substantial capital for growth and innovation.

What critics are saying

  • Patent litigation risks could lead to costly legal battles and financial liabilities.
  • Dependency on strategic partnerships may pose risks if collaborations don't meet expectations.
  • Reliance on external funding through PIPE offerings could be risky if market conditions change.

What makes Prime Medicine unique

  • Prime Medicine uses Prime Editing for precise DNA modifications, setting it apart in biotech.
  • The company targets genetic disorders, a vast market with millions of potential beneficiaries.
  • Prime Medicine's leadership includes industry veterans, enhancing its credibility and operational expertise.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE